结论肺癌多次基因检测结果不一致的原因可能涉及不同的检测方式、不同的检测时间点以及不同的检测样本。尽管如此，我们可以倾向于以最新的有突变的结果为准，并结合其他临床信息进行综合判断。同时，我们强调，面对这种情况，找到专业的肿瘤专家很重要，只有他们能够给出最准确和科学的判断，为患者提供针对性的治疗方案。参考文献：1. Skoulidis F, Papadimitrakopoulou V. Targeting the MAPK pathway in non-small cell lung cancer: Promising preclinical activity with the MEK inhibitor trametinib. Mol Cancer Ther. 2014;13(5):923–9.2. Shaw AT, Engelman JA. ALK in lung cancer: Past, present, and future. J Clin Oncol. 2013;31(8):1105–11.3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.4. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.5. Gandara DR, Hammerman PS, Sos ML, et al. Squamous cell lung cancer: From tumor genomics to cancer therapeutics. Clin Cancer Res. 2015;21(10):2236–43.
